Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.64 |
| ▸ | CASP1 | P29466 | 2/20 | 0.64 |
| ▸ | F2 | P00734 | 2/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CTRC | Q99895 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27501507 | 0.91 | ELANE (0.62) | ELANECASP1F2PRSS1NPC1 | |
| SCHEMBL4424252 | 0.87 | ELANE (0.61) | ELANECASP1F2PRSS1NPC1 | |
| SCHEMBL7340504 | 0.86 | ELANE (0.55) | ELANECASP1F2PRSS1NPC1 | |
| SCHEMBL21685578 | 0.85 | NPC1 (0.50) | ELANECASP1F2PRSS1NPC1 | |
| SCHEMBL7276488 | 0.84 | ELANE (0.64) | ELANECASP1NPC1RAB9ACTRC | |
| SCHEMBL2802859 | 0.84 | ELANE (0.64) | ELANECASP1F2PRSS1NPC1 | |
| SCHEMBL6852033 | 0.84 | KAT2B (0.56) | ELANECASP1F2PRSS1NPC1 | |
| SCHEMBL8642645 | 0.84 | NPC1 (0.60) | ELANECASP1F2PRSS1NPC1 | |
| SCHEMBL2801889 | 0.83 | ELANE (0.65) | ELANECASP1F2PRSS1NPC1 | |
| SCHEMBL8402442 | 0.83 | ELANE (0.52) | ELANECASP1NPC1RAB9ACTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-7772366-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2123665-A2 | Inhibitors of interleukin-1Beta converting enzyme | Vertex Pharmaceuticals Incorporated (US) | 2009-11-25 | — | — | EP | disclosed |
| US-7402586-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-7288624-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-30 | — | — | US | disclosed |
| EP-1036063-B1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060211719-A1 | Heteroaryl aminoguanidine and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-09-21 | — | — | US | disclosed |
| US-7029654-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1451175-A1 | THROMBIN INHIBITORS | University of Ljubljana (SI) | 2004-09-01 | — | — | EP | disclosed |
| EP-0804464-A1 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5658930-A | THROMBIN INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5656627-A | USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0784628-A1 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1997-07-23 | — | — | EP | disclosed |
| EP-0509769-B1 | Heterocyclic amides having HLE inhibiting activity | ZENECA LTD (GB) | 1996-09-11 | — | — | EP | disclosed |
| WO-1996018644-A9 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | — | 1996-08-01 | — | — | WO | disclosed |
| WO-1996018644-A1 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1996-06-20 | — | — | WO | disclosed |
| US-5521179-A | Heterocyclic amides | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| WO-1995035308-A1 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-12-28 | — | — | WO | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211719-A1 | Heteroaryl aminoguanidine and alkoxyguanidines and their use as protease inhibitors | F9, PLG, MMP9 | ELANE 261/4885CASP1 506/4885F2 26/4885 |
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | ELANE 140/4885CASP1 5/4885F2 1406/4885 |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | ELANE 140/4885CASP1 5/4885F2 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.